NCT00388336View on ClinicalTrials.gov

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

March 31, 2005

Conditions
AnemiaNeoplasms
Interventions
DRUG

Epoetin Alfa

All Listed Sponsors
collaborator

Ortho Biotech Clinical Affairs, L.L.C.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00388336 - PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy | Biotech Hunter | Biotech Hunter